Yung Zip Chemical Ind. Co (4102) Fair Value & Analysis
Healthcare · TW · Market cap 797M TWD
Fair value as of: Jul 9, 2026
From 4 valuation models · updated today
Fair value updated Jul 9, 2026 — revised from 62.47 TWD to 4.27 TWD (−93.2%) since Jun 24, 2026. Share price +14.7% over the past month.
Price vs Fair Value (12 months)
12‑month range 16.75 TWD – 23.39 TWD · fair‑value band 2.87 TWD – 5.68 TWD · the 19.90 TWD price screens above the 4.27 TWD fair value. As of Jul 9, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Yung Zip Chemical Ind. Co (4102) currently trades at 19.90 TWD, while our model-based Fair Value estimate is 4.27 TWD — implying the stock looks roughly 78.5% overvalued today. We read business quality at 44/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Yung Zip Chemical Ind. Co generated revenue of 468M TWD at a net margin of -2.4%. Revenue declined 4.5% year over year. It earns a return on equity of -1.0%. Net debt stands at 57.0M TWD. Fundamentals as of Jul 9, 2026
Our scenario range runs from 2.87 TWD (bear case) to 5.68 TWD (bull case); at 19.90 TWD, the current price sits above that range. The share trades about 15% below its 52-week high and 21% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -42% fair-value upside — at -79%, 4102 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 9, 2026. TTM = trailing twelve months.
About the company
Yung Zip Chemical Ind. Co., Ltd., together with its subsidiaries, engages in the manufacturing and trading of active pharmaceutical ingredients in Taiwan, China, Asia, the Americas, and internationally. The company offers active pharmaceutical ingredients and excipients, API intermediates, and specialty chemicals. It is also involved in custom research and manufacturing services; general investments; and food manufacturing. The company was founded in 1978 and is based in Taichung, Taiwan.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Yung Zip Chemical Ind. Co reported revenue of 474M TWD in FY2025 versus 478M TWD in FY2021, a compound −0.2%/yr. Reported net income was −14.4M TWD in FY2025.
Is 4102 fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,136 | $630.79 | -44% |
| Johnson & Johnson, JNJ | 4,128 MXN | 159.68 MXN | -96% |
| AbbVie Inc ABBV | $230.01 | $133.86 | -42% |
| Roche Holding ROGN | 7,050 MXN | 5,672 MXN | -20% |
| Merck & Co MRCK34 | R$77.92 | R$40.37 | -48% |
| AstraZeneca PLC A1ZN34 | R$150.60 | R$23.54 | -84% |
| Novartis AG N1VS34 | R$77.00 | R$70.07 | -9% |
| Novo Nordisk A/S NOVOB | kr 307.75 | kr 542.67 | +76% |
| Amgen Inc AMGN | 6,170 MXN | 253.17 MXN | -96% |
| Gilead Sciences, Inc GIS | €108.32 | €204.69 | +89% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Yung Zip Chemical Ind. Co (4102) undervalued?
What is the fair value of 4102?
What is the quality score of 4102?
What is the revenue of Yung Zip Chemical Ind. Co (4102)?
What is the net profit margin of 4102?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.